Philips VeriSight Pro ICE Catheter Introduced in the United States

July 1, 2021—Royal Philips announced the first minimally invasive heart procedure was performed using the company’s VeriSight Pro real-time three-dimensional (3D) intracardiac echocardiography (ICE) catheter. The VeriSight Pro received FDA 510(k) clearance in September 2020. It is available on a limited basis in the United States, advised Philips.

The left atrial appendage (LAA) occlusion procedure was conducted by Mohamad Adnan Alkhouli, MD, at Mayo Clinic in Rochester, Minnesota.

According to Philips, the VeriSight Pro ICE catheter is used with Philips’ Epiq CVx cardiology ultrasound system to provide two-dimensional (2D) and 3D live image guidance for a wide range of procedures in structural heart disease and electrophysiology.

The company stated that VeriSight Pro uses the same ultrasound technology as transesophageal echocardiography but it is miniaturized to fit on the tip of a 1.98-mm diameter (9-F) catheter that can be navigated to the patient’s heart via their vasculature. General anesthesia is typically not required, reducing patient risk, and allowing treatment for patients who are not good anesthesia candidates.

Based on Philips’ xMatrix 3D ultrasound transducer technology, VeriSight Pro can provide a 90º X 90º 3D field of view and allow physicians to view two scan planes simultaneously. For example, the long and short axes of the LAA to select the appropriately sized device for LAA closure. VeriSight Pro provides 3D volume and color-flow imaging. In addition to 2D and 3D ICE imaging, VeriSight Pro allows users to access new views more easily. Interventionalists can digitally change the scan angle to capture new views without manually repositioning the ultrasound tip, noted the company.